Skip to main content
66°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
1.000
+0.100 (+11.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bluebird Bio
< Previous
1
2
3
4
5
6
7
Next >
New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels
December 11, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
November 22, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
November 05, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row
November 05, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
November 04, 2021
From
bluebird bio, Inc
Via
Business Wire
bluebird bio Completes Planned Business Separation
November 04, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Sets Record Date and Distribution Date for Planned Business Separation
October 18, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Provides Update on Upcoming Planned Business Separation
October 08, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
September 21, 2021
From
bluebird bio, Inc.
Via
Business Wire
2seventy bio Announces Upcoming Investor Events
September 13, 2021
From
bluebird bio
Via
Business Wire
bluebird bio Secures $75 Million in Private Placement Equity Financing
September 08, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events
September 07, 2021
From
bluebird bio, Inc.
Via
Business Wire
BLUEBIRD BIO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE
August 13, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
bluebird bio Reports Second Quarter Financial Results and Provides Operational Update
August 09, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events
August 05, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2021
From
bluebird bio, Inc.
Via
Business Wire
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies
July 28, 2021
From
bluebird bio, Inc. and Resilience
Via
Business Wire
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor
July 21, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU
July 09, 2021
From
bluebird bio, Inc.
Via
Business Wire
BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE
June 11, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual
June 11, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Present at Goldman Sachs Global Healthcare Conference
June 07, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
June 07, 2021
From
bluebird bio
Via
Business Wire
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
May 21, 2021
From
bluebird bio, Inc.
Via
Business Wire
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma
May 19, 2021
From
Bristol Myers Squibb
Via
Business Wire
bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress
May 13, 2021
From
bluebird bio, Inc.
Via
Business Wire
NASDAQ:BLUE Long Term Investor Alert: Investigation of Potential Wrongdoing at Bluebird Bio Inc
May 12, 2021
San Diego, CA -- (SBWIRE) -- 05/12/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of bluebird bio Inc.
Via
SBWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress
May 05, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces May Investor Events
May 03, 2021
From
bluebird bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.